Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

ABI1-based 7-gene expression signature predicts breast cancer metastasis and survival

ABSTRACT: ABI1-based 7-gene expression signature predicts breast cancer metastasis and survival

PROVIDER: PRJNA670946 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

ABI1-based 7-gene expression signature predicts breast cancer metastasis and survival

Project description:Collection of human breast cancer gene expressed measured by GPL2567. This subpopulation of breast cancer has gene expression and clinical data which were used for survival prediction analysis; resulting in emphasizing the ABI1-based 7-gene prognostic signature, as a prospective multi-gene expression clinical biomarker of breast cancer aggressiveness and metastasis, and therapeutic target.

2021-08-18 | GSE159956 | GEO

ABI1-based expression signature predicts breast cancer metastasis and survival.

Project description: Not available

| S-EPMC9297774 | biostudies-literature

Transforming Growth Factor β-Induced Epithelial-to-Mesenchymal Signature Predicts Metastasis-Free Survival in Non-Small Cell Lung Cancer.

Project description:Transforming Growth Factor β-Induced Epithelial-to-Mesenchymal Signature Predicts Metastasis-Free Survival in Non-Small Cell Lung Cancer.

| PRJNA472577 | ENA

Project description:A -catenin-related transcriptional signature predicts survival outcomes in hepatocellular carcinoma patients.

| PRJNA1128715 | ENA

A transcriptional metastatic signature predicts survival in clear cell renal cell carcinoma

Project description:A transcriptional metastatic signature predicts survival in clear cell renal cell carcinoma

| PRJNA739195 | ENA

Unique MicroRNA Expression Signature Predicts Survival, Metastases and Recurrence of HCC

2008-01-14 | GSE6857 | GEO

Unique MicroRNA Expression Signature Predicts Survival, Metastases and Recurrence of HCC

Project description:In this study we investigated the miRNA expression profile of Hepatocellular carcinoma (HCC) specimens from radical resection. We developed a unique 20 miRNA signature that could significantly distinguish HCC venous metastasis from metastasis-free HCC. In contrast to HCC staging systems, this signature was capable of predicting survival and recurrence of HCC patients with multinodular or solitary tumors, including those with early-stage disease. Moreover, the signature was an independent and significant predictor of patient prognosis and relapse when compared to other available clinical parameters. Our study suggests that these 20 miRNAs can enable HCC prognosis and may have clinical utility for the advance identification of HCC patients with a propensity towards metastasis/recurrence. Keywords: disease state design Gene expression profiles were conducted in primary HCC and corresponding noncancerous hepatic tissues from 244 Chinese HCC patients. A total of 134 well-defined cases were used as a training group. Among them, 30 had primary HCC lesions accompanied by tumor emboli and 104 had solitary HCC with no metastasis/recurrence found at follow-up (3 yr). We used a testing group of 110 independent cases. The testing cases included 43 multinodular and 67 solitary HCC. In addition, eight normal liver tissues from disease-free patients were included as normal controls. In the analysis of the 244 HCC cases, RNA was isolated in a pairwise fashion from tumor or non-tumor tissue and samples were selected in random order for miRNA analysis to avoid grouping bias.

2008-01-14 | E-GEOD-6857 | biostudies-arrayexpress

TP53 signature predicts survival outcome in triple-negative breast cancer with neoadjuvant chemotherapy

Project description:TP53 signature predicts survival outcome in triple-negative breast cancer with neoadjuvant chemotherapy

| PRJNA786568 | ENA

Project description:Hepatocellular carcinoma (HCC) is the most common form of liver cancer and a major cause of cancer-related deaths worldwide. Nevertheless, treatment and prognosis are still dependent on clinical and pathological factors, given that molecular biomarkers predicting survival outcomes are lacking. The extensive molecular heterogeneity characterizing HCC is denoted by the large number of signaling pathways involved in tumor initiation and progression. Among these, aberrant activation of the Wnt/-catenin pathway is the most frequent alteration. Various mechanisms can contribute to signaling hyperactivation, including somatic mutations and epigenetic alterations. Here, we have identified a Wnt/-catenin-related transcriptional signature denoting hyperactivated pathway signaling regardless of the presence of pathway-related activating mutations. The WNT signature predicts survival outcomes in two independent HCC patient cohorts and is associated with distinctive immunogenomic features denoting immune exclusion.

2026-07-01 | GSE270897 | GEO

DNA methylation status predicts survival in metastasis free clear cell renal cell carcinoma

Project description:DNA methylation status predicts survival in metastasis free clear cell renal cell carcinoma

| PRJNA453379 | ENA